FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3122855631> ?p ?o ?g. }

• W3122855631 endingPage "605" @default.
• W3122855631 startingPage "593" @default.
• W3122855631 abstract "Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti-programmed cell death ligand 1 (PD-L1), anti-programmed cell death protein 1 (PD-1), and T-Lymphocyte-associated antigen 4 (CTLA-4) inhibitors are now part of the standard of care for advanced NSCLC. However, the prognostic impact of PD-L1 expression in the oligometastatic setting remains unknown. Methods: Patients with oligometastatic NSCLC were identified from the patient database of the Centre hospitalier de l’Université de Montréal (CHUM). “Oligometastatic disease” definition chosen is one synchronous metastasis based on the M1b staging of the eight IASLC (The International Association for the Study of Lung Cancer) Classification (within sixth months of diagnosis) or up to three cerebral metastasis based on the methodology of the previous major phase II randomized study of Gomez et al. We compared the OS between patients receiving aggressive treatment at both metastatic and primary sites (Group A) and patients receiving non-aggressive treatment (Group B). Subgroup analysis was performed using tumor PD-L1 expression. Results: Among 643 metastatic NSCLC patients, we identified 67 patients with oligometastasis (10%). Median follow-up was 13.3 months. Twenty-nine patients (43%) received radical treatment at metastatic and primary sites (Group A), and 38 patients (57%) received non-aggressive treatment (Group B). The median OS (mOS) of Group A was significantly longer than for Group B (26 months vs. 5 months, p = 0.0001). Median progression-free survival (mPFS) of Group A was superior than Group B (17.5 months vs. 3.4 months, p = 0.0001). This difference was still significant when controlled for primary tumor staging: stage I (p = 0.316), stage II (p = 0.024), and stage III (p = 0.001). In the cohort of patients who were not treated with PD-L1 inhibitors, PD-L1 expression negatively correlated with mOS. Conclusions: Aggressive treatments of oligometastatic NSCLC significantly improve mOS and mPFS compared to a more palliative approach. PD-L1 expression is a negative prognostic factor which suggests a possible role for immunotherapy in this setting." @default.
• W3122855631 created "2021-02-01" @default.
• W3122855631 creator A5003235921 @default.
• W3122855631 creator A5018835840 @default.
• W3122855631 creator A5022592378 @default.
• W3122855631 creator A5029208296 @default.
• W3122855631 creator A5038631903 @default.
• W3122855631 creator A5039840041 @default.
• W3122855631 creator A5046516066 @default.
• W3122855631 creator A5054415157 @default.
• W3122855631 creator A5056103345 @default.
• W3122855631 creator A5064804402 @default.
• W3122855631 creator A5071219496 @default.
• W3122855631 creator A5082440799 @default.
• W3122855631 date "2021-01-20" @default.
• W3122855631 modified "2023-10-01" @default.
• W3122855631 title "Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC" @default.
• W3122855631 cites W1987288037 @default.
• W3122855631 cites W2059812828 @default.
• W3122855631 cites W2062180205 @default.
• W3122855631 cites W2129056013 @default.
• W3122855631 cites W2319874020 @default.
• W3122855631 cites W2461987940 @default.
• W3122855631 cites W2527905628 @default.
• W3122855631 cites W2529254901 @default.
• W3122855631 cites W2546935275 @default.
• W3122855631 cites W2743614427 @default.
• W3122855631 cites W2781879617 @default.
• W3122855631 cites W2808354728 @default.
• W3122855631 cites W2811161985 @default.
• W3122855631 cites W2890066506 @default.
• W3122855631 cites W2896342720 @default.
• W3122855631 cites W2912800027 @default.
• W3122855631 cites W2915544780 @default.
• W3122855631 cites W2944301866 @default.
• W3122855631 cites W2965638931 @default.
• W3122855631 cites W3032651552 @default.
• W3122855631 cites W4240340450 @default.
• W3122855631 doi "https://doi.org/10.3390/curroncol28010059" @default.
• W3122855631 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7924378" @default.
• W3122855631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33498159" @default.
• W3122855631 hasPublicationYear "2021" @default.
• W3122855631 type Work @default.
• W3122855631 sameAs 3122855631 @default.
• W3122855631 citedByCount "10" @default.
• W3122855631 countsByYear W31228556312021 @default.
• W3122855631 countsByYear W31228556312022 @default.
• W3122855631 countsByYear W31228556312023 @default.
• W3122855631 crossrefType "journal-article" @default.
• W3122855631 hasAuthorship W3122855631A5003235921 @default.
• W3122855631 hasAuthorship W3122855631A5018835840 @default.
• W3122855631 hasAuthorship W3122855631A5022592378 @default.
• W3122855631 hasAuthorship W3122855631A5029208296 @default.
• W3122855631 hasAuthorship W3122855631A5038631903 @default.
• W3122855631 hasAuthorship W3122855631A5039840041 @default.
• W3122855631 hasAuthorship W3122855631A5046516066 @default.
• W3122855631 hasAuthorship W3122855631A5054415157 @default.
• W3122855631 hasAuthorship W3122855631A5056103345 @default.
• W3122855631 hasAuthorship W3122855631A5064804402 @default.
• W3122855631 hasAuthorship W3122855631A5071219496 @default.
• W3122855631 hasAuthorship W3122855631A5082440799 @default.
• W3122855631 hasBestOaLocation W31228556311 @default.
• W3122855631 hasConcept C121608353 @default.
• W3122855631 hasConcept C126322002 @default.
• W3122855631 hasConcept C143998085 @default.
• W3122855631 hasConcept C2776256026 @default.
• W3122855631 hasConcept C2777701055 @default.
• W3122855631 hasConcept C2778164965 @default.
• W3122855631 hasConcept C2779013556 @default.
• W3122855631 hasConcept C71924100 @default.
• W3122855631 hasConceptScore W3122855631C121608353 @default.
• W3122855631 hasConceptScore W3122855631C126322002 @default.
• W3122855631 hasConceptScore W3122855631C143998085 @default.
• W3122855631 hasConceptScore W3122855631C2776256026 @default.
• W3122855631 hasConceptScore W3122855631C2777701055 @default.
• W3122855631 hasConceptScore W3122855631C2778164965 @default.
• W3122855631 hasConceptScore W3122855631C2779013556 @default.
• W3122855631 hasConceptScore W3122855631C71924100 @default.
• W3122855631 hasIssue "1" @default.
• W3122855631 hasLocation W31228556311 @default.
• W3122855631 hasLocation W31228556312 @default.
• W3122855631 hasOpenAccess W3122855631 @default.
• W3122855631 hasPrimaryLocation W31228556311 @default.
• W3122855631 hasRelatedWork W1974869856 @default.
• W3122855631 hasRelatedWork W2009226744 @default.
• W3122855631 hasRelatedWork W2359429907 @default.
• W3122855631 hasRelatedWork W2517198330 @default.
• W3122855631 hasRelatedWork W2799453846 @default.
• W3122855631 hasRelatedWork W2981133333 @default.
• W3122855631 hasRelatedWork W2995717006 @default.
• W3122855631 hasRelatedWork W3014533067 @default.
• W3122855631 hasRelatedWork W3217115064 @default.
• W3122855631 hasRelatedWork W4221050677 @default.
• W3122855631 hasVolume "28" @default.
• W3122855631 isParatext "false" @default.
• W3122855631 isRetracted "false" @default.
• W3122855631 magId "3122855631" @default.
• W3122855631 workType "article" @default.